Appointed
Scott J. Saunders
director
NUTX ·
Nutex Health Inc.
appointed Scott J. Saunders, age 61, to serve as a director of the Company for a term commencing on April 11, 2024
Ready 8-Ks
50
Latest filing
August 24, 2026, 4:02 PM ET
Top materiality
0.85
Event mix
earnings ×18 · other_material ×13 · regulatory ×6
Sentiment
19 pos · 13 neg · 18 neu
Latest earnings
reported 2026-Q2
Executive change
recent →
Recent 8-K filings for NUTX
Highest-materiality recent filing
Nutex Health Q2 net income $65.8M vs loss $17.7M YoY; revenue down 13.6%
- Diluted EPS $9.38 vs $(2.95) in Q2 2025; six-month net income $112.6M, EPS $15.87.
- Revenue $210.8M (-13.6% YoY) due to prior-year IDR benefits; hospital visits +9.6%.
-
Nutex Health discloses unauthorized data access and exfiltration from its network
On Aug 24, 2026, Nutex Health reported unauthorized third-party access and exfiltration of data from its computer network.
-
On Aug 11, 2026, en banc Fifth Circuit in Texas Medical Association v. HHS vacated July 2021 Rule allowing ghost rates and excluding bonus/incentive payments from QPA.
-
Nutex Health Q2 net income $65.8M vs loss $17.7M YoY; revenue down 13.6%
Diluted EPS $9.38 vs $(2.95) in Q2 2025; six-month net income $112.6M, EPS $15.87.
-
Nutex Health amends HaloMD agreement; expects lower arbitration costs from CMS fee cut
First Amendment to Payment Dispute Resolution Services Agreement with HaloMD, effective June 30, 2026.
-
Nutex Health Q1 2026 net income $46.8M, diluted EPS $6.52, revenue $216.5M
Revenue $216.5M (+2.2% YoY); hospital division revenue $207.6M.
-
Nutex Health annual meeting elects all 7 directors, approves say-on-pay and auditor ratification
All seven director nominees elected; Thomas T. Vo received 2,554,009 votes 'for' and 89,198 withheld.
-
Nutex Health FY2025 revenue up 82% to $875M, diluted EPS $10.48; announces $25M buyback
FY2025 total revenue $875.3M, up 82.4% YoY; net income $70.8M vs $52.1M; diluted EPS $10.48 vs $9.69.
-
Nutex Health files auditor consent to incorporate 2023 audit report by reference
Marcum LLP consent to incorporate Dec 31, 2023 audit report into registration statements.
-
Nutex Health Q3 2025 revenue $267.8M (+240% YoY), net income $55.4M vs loss $8.8M
Total revenue $267.8M for Q3 2025, up 240% YoY; hospital division revenue $260.2M, up 263% YoY.
-
Nutex Health restates 2024 results: revenue $479.9M (+93.8% YoY), net income $52.1M vs loss $45.8M
Restated full-year 2024: revenue $479.9M (up 93.8% YoY); net income $52.1M vs net loss $45.8M in 2023.
-
Nutex Health restates Q1 2025: revenue $211.8M, net income $21.2M, diluted EPS $3.33
Total revenue $211.8M, up 214% YoY from $67.5M.
-
Nutex Health H1 2025 revenue $455.8M (+217.5% YoY), net income $3.5M, launches $25M buyback
H1 2025 revenue $455.8M (+217.5% YoY); net income $3.5M vs net loss $0.7M in H1 2024.
-
Preliminary Q3 2025 patient volume of 46,293 visits, up 11.1% vs Q3 2024.
-
Nutex Health appoints Wesley Bamburg as COO effective Oct 13, 2025
Wesley Bamburg, former COO at HCA Houston Healthcare North Cypress, appointed COO effective October 13, 2025.
-
Plaintiff Juan Camilo Jimenez filed derivative action in S.D. Texas (Case 4:25-cv-04253) on Sept 8, 2025.
-
Nutex Health appoints Michael L. Reed as Lead Independent Director
Michael L. Reed appointed Lead Independent Director effective Sept 2, 2025.
-
Securities class action lawsuit filed against Nutex Health tracking short seller report
Putative class action filed Aug 22, 2025 in SD Texas (Case 4:25-cv-03999) claiming Sections 10(b) and 20(a) violations.
-
Nutex Health restates FY2024 and Q1 2025; receives Nasdaq delisting notice for late filing
Restatement due to misclassification of obligations for under-construction hospitals; liabilities increase $10-20M (Dec 2024) and $20-50M (Mar 2025); equity decreases correspondingly.
-
Nutex Health reports Q2 prelim revenue $244M (+221% YoY); announces $25M buyback, delays 10-Q
Q2 2025 total revenue $244.0M, up 220.7% from $76.1M in Q2 2024; gross profit $124.9M (51.2% margin) vs $22.6M (29.7%).
-
Nutex Health shareholders approve director elections, equity plan amendment at annual meeting
All seven director nominees elected; top vote-getter Frank Jaumot with 2,798,958 for, lowest Michael Reed with 2,253,524 for.
-
Nutex Health COO Joshua DeTillio resigns effective Aug 8, 2025 to become CEO elsewhere
Joshua DeTillio notified Nutex Health of his resignation as COO effective August 8, 2025.
-
Nutex Health dismisses CBIZ as auditor, appoints Grant Thornton; material weaknesses cited
Audit committee dismissed CBIZ CPAs P.C. effective May 15, 2025; CBIZ did not issue an audit report.
-
Nutex Health Q1 revenue surges 214% to $211.8M; net income $14.6M vs loss $0.4M
Diluted EPS $2.56 vs ($0.08) in Q1 2024; EBITDA $43.1M (+507% YoY).
-
Auditor Marcum LLP resigns; Nutex Health discloses material weaknesses, hires CBIZ
Marcum LLP resigned as auditor on April 25, 2025, due to acquisition by CBIZ CPAs P.C.
-
FY 2024 total revenue $479.9M (+93.8% YoY); net income $52.2M vs net loss $45.8M in 2023.
-
Nutex Health reports >80% arbitration success rate in Q4 2024 under No Surprises Act
Since July 2024, Nutex submits 60-70% of billable visits to arbitration monthly.
-
Nutex Health Q3: Revenue $78.8M (+26%), Adj EBITDA $13.5M (+938%), Operating income positive
Q3 total revenue $78.8M vs $62.7M YoY (+26%); mature hospitals grew 20.7%.
-
Nutex Health Q2 revenue up 29% to $76.1M; Adjusted EBITDA up 200% to $12.0M
Net loss attributable to Nutex of $0.4M vs $3.5M loss in Q2 2023; H1 net loss $0.7M vs $8.6M.
-
Nutex Health regains Nasdaq minimum bid price compliance after reverse stock split
Received compliance notice from Nasdaq on July 24, 2024.
-
Nutex Health effects 1-for-10 reverse stock split effective July 2, 2024
Board approved 1-for-10 reverse stock split; filed July 1, effective 11:59 pm ET July 2, 2024.
-
Nasdaq Hearings Panel granted Nutex exception until July 22, 2024 to execute reverse split and regain $1.00 minimum bid.
-
Nutex Health receives Nasdaq delisting notice for bid price non-compliance; appeals, hearing July 9
Nasdaq notified Nutex that it failed to regain the $1.00 minimum bid price by May 20, 2024.
-
Nutex Health Q1 2024 revenue $67.5M (+20% YoY); net loss narrows to $0.4M
Revenue $67.5M vs $56.3M YoY; hospital visits up 21.1% to 40,068.
-
Nutex Health effects 1-for-15 reverse stock split; trading on split-adjusted basis from April 10
Board approved 1-for-15 reverse split effective April 9, 2024 after filing Certificate of Amendment with Delaware.
-
Nutex Health appoints Scott J. Saunders as independent director to fill vacancy
Scott J. Saunders, age 61, appointed to Board effective April 11, 2024, replacing deceased director John Waters.
-
Nutex Health reports Q4 net loss of $31.6M on $69.7M revenue; FY 2023 revenue up 13%
Q4 revenue $69.7M (+30% YoY); net loss $31.6M including $29.1M non-cash asset impairment.
-
Nutex Health director Dr. Danniel Stites to depart; Dr. Kelvin Spears appointed
Dr. Stites leaves Board at end of one-year term (April 1, 2024); no disagreement with management.
-
Nutex Health terminates $100M Yorkville prepaid advance agreement; pays off $3.1M balance
Termination effective Feb 15, 2024 by mutual consent; no outstanding balances or fees due.
-
Nutex Health CEO Tom Vo voluntarily reduces base salary by 50% to $500K
CEO Vo recommended and received approval for 50% base salary cut from $1M to $500K effective Feb 1.
-
Nutex Health raises $10M via 66.7M share/warrant offering at $0.15/unit
Offering of 66.7M shares and warrants on a 1:1 basis at $0.15 per unit; gross proceeds ~$10M.
-
Nutex Health presents at J.P. Morgan Healthcare Conference; no financials disclosed
CEO Tom Vo and President Warren Hosseinion presenting at 42nd Annual J.P. Morgan Healthcare Conference on Jan 11, 2024.
-
Nutex Health receives second 180-day Nasdaq compliance period for bid price deficiency
Company failed to regain minimum $1 bid price by Nov 20, 2023 initial deadline.
-
Nutex Health Q3 revenue $62.7M, up 121% YoY; Adj. EBITDA $1.3M; guides five new hospitals in 2024
Net loss attributable to Nutex Health $(5.5)M; Q3 2022 loss $(412.2)M included $398M goodwill impairment.
-
Nutex Health names Joshua DeTillio COO; base salary $425K, bonus up to 70%
Joshua DeTillio appointed COO effective October 2, 2023; 20+ years healthcare leadership experience.
-
Nutex Health acquires PHA and MCIC, adding 112 PCPs and 4,400 patients in Florida
Acquired Population Health Associates and Managed Care Insurance Consultants, adding ~112 primary care physicians and 4,400 managed care patients.
-
Nutex Health Q2 2023 net loss $3.5M, revenue $58.9M; plans 1-2 more hospitals in 2023
Net revenue $58.9M in Q2 2023, essentially flat vs $58.0M in Q2 2022.
-
Shareholders approved increase in authorized common shares from 900M to 950M (For: 329.7M, Against: 154.7M).
-
Nutex Health receives Nasdaq notice for bid price below $1.00; 180 days to regain compliance
Received Nasdaq deficiency letter on May 22, 2023; bid price below $1.00 for 30 consecutive business days.
-
Nutex Health Q1 net loss $5.1M; revenue falls 29% YoY to $56.3M
Net loss attributable to Nutex Health of $5.1M ($0.01 EPS) vs net income of $21.4M ($0.04 EPS) in Q1 2022.
-
Nutex Health begins using investor presentation; no material new disclosures
Senior management of Nutex Health will use a new investor presentation effective May 1, 2023.
Executive changes
Departed
Dr. Danniel Stites
Director
NUTX ·
Nutex Health Inc.
Dr. Danniel Stites informed the Board of Directors (the “Board”) of Nutex Health Inc. (the “Company”) that he had decided to depart from the Board at the end of his one year term commitment which had commenced on April 1, 2023.
Appointed
Dr. Kelvin Spears
Director
NUTX ·
Nutex Health Inc.
On February 28, 2024, the Board elected Dr. Kelvin Spears, 63, as a member of the Board effective April 1, 2024.
Appointed
Joshua DeTillio
Chief Operating Officer
NUTX ·
Nutex Health Inc.
On September 5, 2023, the Company announced the appointment of Joshua DeTillio, age 47, as the Company’s Chief Operating Officer, effective on October 2, 2023 (the "Commencement Date").
Departed
Dr. Matthew Young
Director
NUTX ·
Nutex Health Inc.
On March 31, 2023, Dr. Matthew Young informed the Board of Directors (the “Board”) of Nutex Health Inc. (the “Company”) that he had decided to depart from the Board at the end of his one year term commitment which had commenced on April 1, 2022.
Appointed
Dr. Danniel Stites
Director
NUTX ·
Nutex Health Inc.
On April 1, 2023, the Board elected Dr. Danniel Stites, age 42, as a member of the Board.
Appointed
Jon Bates
Chief Financial Officer
NUTX ·
Nutex Health Inc.
On June 10, 2022, the Company announced the appointment of Jon Bates, age 52, as the Company’s Chief Financial Officer, effective on June 30, 2022
Departed
Michael Bowen
Chief Financial Officer
NUTX ·
Nutex Health Inc.
On June 10, 2022, Nutex Health Inc. (the “Company”) announced that Michael Bowen will retire as Chief Financial Officer of the Company.
Appointed
Michael L. Reed
Director
NUTX ·
Nutex Health Inc.
In connection with the Merger, the Company’s stockholders elected John Waters, CPA, Cherly Grenas, R.N. M.S., Michael L. Reed and Mitchell Creem as independent directors of the Company.
Appointed
Cherly Grenas
Director
NUTX ·
Nutex Health Inc.
In connection with the Merger, the Company’s stockholders elected John Waters, CPA, Cherly Grenas, R.N. M.S., Michael L. Reed and Mitchell Creem as independent directors of the Company.
Appointed
John Waters
Director
NUTX ·
Nutex Health Inc.
In connection with the Merger, the Company’s stockholders elected John Waters, CPA, Cherly Grenas, R.N. M.S., Michael L. Reed and Mitchell Creem as independent directors of the Company.
Appointed
Mitchell Creem
Director
NUTX ·
Nutex Health Inc.
In connection with the Merger, the Company’s stockholders elected John Waters, CPA, Cherly Grenas, R.N. M.S., Michael L. Reed and Mitchell Creem as independent directors of the Company.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.70 · Most common event earnings